50274-95-8

Basic information

• Product Name: alpha,2-dichloro-4-nitrotoluene
• Synonyms: alpha,2-dichloro-4-nitrotoluene;Benzene, 2-chloro-1-(chloroMethyl)-4-nitro-;2-chloro-4-nitrobenzyl chloride;2-chloro-1-(chloromethyl)-4-nitrobenzene
• CAS NO: 50274-95-8
• Molecular Formula: C₇H₅Cl₂NO₂
• Molecular Weight: 206.0261
• EINECS: 256-517-9
• Mol File: 50274-95-8.mol
• Article Data: 3

Chemical Properties

• Melting Point: 48-50 °C
• Boiling Point: 311.5±27.0 °C(Predicted)
• Appearance: /
• Density: 1.4062 (rough estimate)
• Refractive Index: 1.6100 (estimate)
• CAS DataBase Reference: alpha,2-dichloro-4-nitrotoluene(CAS DataBase Reference)
• NIST Chemistry Reference: alpha,2-dichloro-4-nitrotoluene(50274-95-8)
• EPA Substance Registry System: alpha,2-dichloro-4-nitrotoluene(50274-95-8)

Safety Data

• Hazardous Substances Data: 50274-95-8(Hazardous Substances Data)

Upstream product

• 52301-88-9 (2-chloro-4-nitrophenyl)methanol 

Downstream Products

• 28163-00-0 4-nitro-2-chlorobenzonitrile 
• 858678-29-2 1-(2-chloro-4-nitro-benzyl)-piperidine 
• 689300-35-4 (2-chloro-4-nitro-benzyl)-diethyl-amine 
• 78710-93-7 Phosphoric acid mono-{(2R,3S,4R,5R)-5-[6-amino-8-(2-chloro-4-nitro-benzylsulfanyl)-purin-9-yl]-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl} ester 

Relevant articles and documents

INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER

The present invention encompasses compounds of general formula (1) wherein R1 to R4 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.

3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS

The invention relates to amid compounds of general formula (I), wherein groups and residuals A, B, b, W, X, Y, Z, R1, R2 and R3 have significances given in a claim 1. In addition, said invention relates to drugs containing at least one type of inventive amid. Because of the antagonist activity of an MCH-receptor, the inventive drugs are suitable for treating metabolic disturbances and/or eating disorders, in particular adiposity, bulimia, anorexia, hyperphagia and diabetes.